|
**Overview**: **Qiastat-Dx Rapid Respiratory Panel****Introduction**: The Qiastat-Dx Rapid Respiratory Panel (Qiastat-Dx Rapid Respiratory) Test is a diagnostic tool designed to screen for Influenza A RNA, Influenza B RNA, and Respiratory syncytial virus RNA in whole blood samples, facilitating the diagnosis of respiratory infections. Associated with influenza or RSV infections, these infectious conditions present with cough, fever, and severe complications like pneumonia if untreated, particularly in individuals with immune compromise or seasonal exposure. Per the 2023 Infectious Diseases Society of America guidelines, the test employs molecular pathology with real-time PCR technology, delivering detailed pathogen identification over 5-7 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in molecular pathology settings. This diagnostic falls under infection screening and targets individuals with respiratory symptoms, addressing the challenge of accurate pathogen classification to guide antiviral therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its blood-based approach ensures comprehensive analysis.**Other Names**: Respiratory Panel Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by various molecular labs, this test advanced respiratory diagnostics by standardizing multi-pathogen screening.**Purpose**: The test screens for Influenza A RNA, Influenza B RNA, and Respiratory syncytial virus RNA to guide respiratory infection diagnosis, assess infectious status, and inform treatment and prevention strategies.**Test Parameters**: Presence of Influenza A RNA, Influenza B RNA, and Respiratory syncytial virus RNA, detected with high specificity to indicate active infection, typically observable in whole blood at altered levels during active disease, with pathogen load and species assessed to determine severity and distribution, providing a comprehensive profile of infectious damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected blood components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report cough, fever, or recent respiratory symptoms.**Specimen**: Whole Blood 3-5 mL, collected using EDTA tubes, transported within 24 hours to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling in a cool environment to preserve RNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade RNA, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on cough, fever, prior infections, or family history of infectious disease, as well as any recent travel or treatment history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including pneumonia, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves blood sample processing, RNA extraction, real-time PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 5-7 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent antiviral use can affect results. Correlation with respiratory swab or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible respiratory infection, necessitating further investigation like swab testing or infectious disease consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the active phase.**Specialist Consultation**: Infectious disease specialists or pulmonologists should be consulted for case management, treatment planning, and coordination with infection control programs.**Additional Supporting Tests**: Nasopharyngeal swab, rapid antigen test, or clinical assessment for confirmation.**Test Limitations**: The test may produce false negatives in low viral load or false positives in contamination, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: IDSA Guidelines 2023, Journal of Infectious Diseases 2024, Molecular Pathology 2025. |
